CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 4528-A |

# Specialty Guideline Management Cosela

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Cosela | trilaciclib |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Extensive-stage Small Cell Lung Cancer1

Authorization of 6 months may be granted to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer when all of the following criteria are met:

* The member will be receiving either of the following chemotherapeutic regimens:
  + A platinum/etoposide-containing regimen.
  + A topotecan-containing regimen.
* The requested medication will be given within 4 hours prior to the start of chemotherapy on each day chemotherapy is administered.
* The requested medication will not be used with granulocyte colony-stimulating factors (G-CSFs) and/or erythropoiesis-stimulating agents (ESAs) as primary prophylaxis during cycle 1.

## Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria.

## References

1. Cosela [package insert]. Durham, NC: G1 Therapeutics, Inc; August 2023.